In 2021, Cures Within Reach began funding Dr. Joseph Rower at the University of Utah to support a Phase I clinical study to associate valganciclovir exposures with immune responses and hearing outcomes in pediatric congenital cytomegalovirus (cCMV) patients.

Dr. Rower is an expert in clinical pharmacology, with specialties in pharmacometric and statistical modeling, and bioanalytical assays. A significant portion of his research has been focused on antiviral drugs. He has a deep interest in pediatrics and has dedicated a share of his research efforts to revolutionizing the clinical care of children by analyzing the impact of age on pharmacokinetic-pharmacodynamic relationships.

His professional goal is to develop a deeper understanding of the connection between clinical outcomes and pharmacokinetics to improve patient care through personalized medicine.

PROFILE
- Dr. Joseph Rower is a Research Assistant Professor in the Department of Pharmacology and Toxicology.
- Dr. Rower completed his PhD training at the University of Colorado Anschutz Medical Campus.

CWR FUNDING
- A $50,000 Phase I clinical study is evaluating valganciclovir exposures in pediatric cCMV patients.
- Dr. Rower and this trial represent two of Cures Within Reach’s communities: Rare Diseases
  Pediatrics

Cures Within Reach leverages the speed, safety and cost-effectiveness by testing approved therapies for new indications, driving more treatments to more patients more quickly.

www.cureswithinreach.org    847.745.1252    info@cureswithinreach.org

Cures Within Reach is a 501(c)3 tax-exempt organization